On July 31, 2025, notice was published in the Federal Register by the Health Resources and Services Administration (“HRSA”) of a “340B Rebate Model Pilot Program” (“340B Pilot Program”). The 340B ...

The 340B Drug Pricing Program was originally constructed so safety-net health care facilities could stretch scarce resources in caring for low-income patients. However, the program has experienced ...

The rapid expansion of the federal 340B drug pricing program is significantly affecting Medicaid budgets, particularly in states where managed care plans oversee prescription drug benefits. New ...

This week, in response to years of efforts led by Kalderos and other 340B program stakeholders to implement a rebate model in the federal drug pricing program, the U.S. Department of Health and Human ...

The number of 340B providers has grown from about 10,000 to 66,000 in the past 15 years, while the number of contract pharmacies increased from 1,300 to 253,000 over the same time. The dramatic growth ...

The Trump administration is reportedly “in negotiation” with pharmaceutical manufacturers to voluntarily lower their prices based on the so-called most favored nation (MFN) pricing policy, with GLP-1 ...

Reforming the federal 340B Drug Pricing Program is a fast and efficient way to reduce drug costs and protect patients. These days, some 340B hospitals are taking advantage of low-income and uninsured ...

The 340B Drug Pricing Program allows certain medical facilities to buy drugs at a discount to support care for low-income patients. Rhode Island's new law, Chapter 288, prevents drug makers from ...

Drug companies are at it again. They will not relent in their multiyear campaign to dismantle the 340B Drug Pricing Program. Drug companies are at it again. They will not relent in their multiyear ...

Drug companies are more likely than hospitals to violate 340B regulations, according to a recent American Hospital Association report. The 340B Drug Pricing Program has been under constant attack on ...

The 340B Drug Pricing Program was created to help low-income patients access medications at reduced costs. Ryan Augsburger argues that expanding the program could increase costs for employers and ...